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Introduction
Auditory verbal hallucinations (AVHs) are common symptoms of mental disorders such as schizophrenia, bipolar disorder, and post traumatic stress disorder (PTSD), and are closely associated with self-harm and suicide [1] . In patients with PTSD, the prevalence of AVHs is estimated at 50-67% [2] . As patients with PTSD who experience AVHs have a higher disability and mortality rate compared to patients with PTSD who do not experience AVHs [3] , early intervention in patients with PTSD and AVHs is recommended [4] .
Although many studies recommend psychotherapy as the first intervention strategy for patients with PTSD, a meta-analysis reported that aripiprazole (an atypical anti-psychotic) can alleviate most of the symptoms of PTSD [4] . A recent review proposed that atypical anti-psychotics have a potential role in the treatment of AVHs in patients with PTSD [5] .
Advanced magnetic resonance imaging (MRI) techniques have demonstrated brain structural and functional impairments in patients with PTSD. Previous reports
show that there are functional disturbances in several neural networks in the brain of patients with PTSD, especially in the default mode network (DMN) and the salience network (SN) [6, 7] . Several studies have revealed that symptoms of AVHs are related A C C E P T E D M A N U S C R I P T to functional disturbances in the DMN and SN [8] [9] [10] . One review noted that AVHs in patients with PTSD are weakly associated with functional impairments in the DMN [11] . Dysfunction in the SN has been observed in various psychiatric disorders, including schizophrenia, PTSD, and Alzheimer's disease [12] . The SN is a large scale brain network composed of the anterior insula and dorsal anterior cingulate cortex.
The SN includes three subcortical structures: the amygdala, the ventral striatum, and the substantia nigra/ventral tegmental area [13] . The SN is involved in detecting and filtering salient stimuli and recruiting relevant functional networks. The SN contributes to a variety of complex functions, including communication and self-awareness through the integration of sensory, emotional, and cognitive information [14] .
The objective of this study was to determine whether add-on aripiprazole treatment can alleviate AVHs in patients with PTSD, and explore the relationship between the treatment effect of add-on aripiprazole and functional changes in the SN.
Material and methods

Participants
Data for 150 patients with chronic PTSD experiencing AVHs were collected from the MRI databases at three research centers. PTSD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV).
AVHs were diagnosed using closed questioning: "Did you at any time hear voices
saying quite a few words or sentences when there was no one around that might account for it?" [15] . Patients with alcohol, other substance abuse, and moderate or heavy nicotine use defined by Fagerstrom Test for Nicotine Dependence (FTND), [16] were excluded. The protocol of this study was approved by Ethics Review Board of Tianjin Mental Health Center, and all subjects were provided written informed consent. Study assessments were carried out in compliance with the Declaration of Helsinki and approved by the Institutional Ethics Committees.
Treatments
During the study patients followed their existing treatment plans, which included psychotherapies and antidepressants such as selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Aripiprazole was added to the patients' treatment plan. The dosage of aripiprazole was gradually increased according to a comprehensive assessment of the therapeutic benefit/risk ratio by two senior psychiatrists at each center. Before administration of aripiprazole, PTSD symptoms and severity of AVHs were assessed by experienced psychiatrists using the Auditory Hallucination Rating Scale (AHRS) and Clinician Administered PTSD Scale (CAPS), respectively. The patients underwent a brain MRI scan. After 24-weeks of treatment, the severity of AVHs and symptoms of PTSD were reassessed, and additional brain imaging data were acquired.
MRI data acquisition
MRI data were obtained using a 3-T GE Discovery MR750 scanner (General 
Structural data analysis
Structural images were processed using VBM8 (http://www.fil. ion.ucl.ac.uk/spm) software. Structural images were normalized and segmented into cerebrospinal fluid (CSF), white matter (WM), and gray matter (GM). Brain parenchyma volume was calculated for each patient as the sum of the gray matter and white matter volumes.
fMRI connectivity analysis
Group level spatial independent component analysis (group-ICA) was performed for all 53 patients using the infomax algorithm [17] within the GIFT software (http://icatb.sourceforge.net/, version, v2.0e) under MATLAB R2011a (Mathworks Inc., Sherbon, MA) programming, as previously described [18] [19] [20] . Group-ICA was conducted on the pooled dataset. A modified minimum description length approach was used to estimate the optimal number of independent components at twenty [21, 22] . The ICASSO algorithm implemented in GIFT was applied to enhance the robustness of the independent components to initial algorithm conditions by repeating the ICA estimation twenty times. Each patient's spatial maps and corresponding time courses were calculated and converted to z-scores, which denoted the strength of each
voxel's contribution to the component's time course [23] .
Component identification
Components related to the SN were identified using the spatial sorting function in GIFT [24] . The mask included the anterior cingulate cortex (ACC), medial prefrontal cortex (mPFC), mid cingulate gyrus, bilateral superior temporal gyrus including the cingulate gyrus, amygdala, and insula cortex. Clusters significant after FWE correction (P < 0.05) that survived a threshold of P < 0.005 at the whole brain level and a cluster threshold of k = 10 (uncorrected) [25] were used to assess small volume correction [26] . Brain network templates were obtained from the Functional 
Results
A total of 150 patients with PTSD and AVHs were enrolled in this study, and 115
patients received add-on aripiprazole treatment. Overall, 76 patients completed
24-weeks of treatment; 39 patients discontinued treatment due to adverse events or poor compliance. The high efficacy group comprised 24 patients in whom AHRS scores were reduced ≥ 50% following add-on aripiprazole treatment. The low efficacy group comprised 29 patients in whom AHRS scores were reduced <50% following add-on aripiprazole treatment. Among the patients that completed treatment, data for 23 patients were discarded due to imbalances in socio-demographic characteristics and severity of PTSD symptoms between the high efficacy and the low efficacy groups. Finally, data for 53 patients were analyzed (Figure 1 ).
The socio-demographic and clinical characteristics of the 53 patients are shown in Table 1 . In all patients, PTSD symptoms improved after add-on aripiprazole treatment, simultaneously, the spontaneous neural activity in the SN decreased after add-on aripiprazole treatment. Figure 2 represents spontaneous neural activity in the salience network in the 24 patients with PTSD in whom AHRS scores were reduced ≥ 50%. Figure 3 represents spontaneous neural activity in the salience network in the patients with PTSD in whom AHRS scores were reduced <50%. Both Figure 2A and Figure 2B represent spontaneous neural activity in the salience network; however, the activity pattern of the salience network is differentially affected by aripiprazole in the two groups of patients. In the 24 PTSD patients in whom AHRS scores were reduced ≥ 50%, aripiprazole induced wider activation of the salience network, including more brain regions (Figure 2A ), than in the 29 patients in whom AHRS scores were reduced <50%( Figure 2B) .
In this study, we also compared the neural activity in the salience network before and after treatment in each group. Therefore, we used the paired t test and did not adopt a method for multiple comparisons. In addition, we evaluated functional connectivity between the dorsal ACC and vmPFC before and after aripiprazole treatment in each group of patients. These brain regions are typically used to analyze alterations in functional connectivity in the salience network. Findings showed that alterations in functional connectivity in the salience network were correlated with the reduction in AHRS scores in the 24 patients with PTSD in whom AHRS scores were reduced ≥ 50%( r=0.246, p<0.001) ( Figure 3A and Figure 3B ). Alterations in functional connectivity in the salience network were not correlated with the reduction in AHRS scores in the 29 patients with PTSD in whom AHRS scores were reduced <50%.
Discussion
This is the first study to investigate the treatment effect of atypical antipsychotics on AVHs and the functional connectivity of the brain network in patients with PTSD. 
Limitations
This study provides novel insights into the pathological features and treatment of AVHs in patients with PTSD. There were some limitations that should be addressed in
future investigations. First, we conducted an artificially controlled post-treatment outcomes analysis. Therefore, the strength of our evidence is weaker than that generated in a randomized clinical trial. Future investigations should use a more robust study design. Second, the aim of this research was to explore neuroimaging alterations specific to AVHs, and we did not focus on other symptoms of PTSD, which may have affected the accuracy of our results. Third, the data we collected were from three research centers, as recruiting patients with PTSD and AVHs for clinical studies is challenging. Consistency in MRI data acquisition across research centres was maintained by using the same scanners and parameters and ensuring the researchers received appropriate training. A larger study population recruited through a single research centre will provide a more consistent result. Fourth, in this study, most patients developed PTSD after experiencing road traffic accidents that involved fatalities, which may have resulted in selection bias. Future studies should include patients that developed PTSD after a variety of events. Fifth, add-on therapy with atypical antipsychotics is not first-line therapy in PTSD; therefore, patients with add-on psychotherapy should also be investigated. Sixth, almost all the patients were on stable doses of antidepressants so that we cannot attribute our findings solely to aripiprazole. Seventh, we only focused on the SN; future studies should investigate the effect of interventions in patients with AVHs and PTSD on other brain neural networks, including the DMN, CEN, and attention network. Eighth, we did not explore the change in brain structure in patients with PTSD and AVHs treated with
add-on aripiprazole; the structural index maybe more stable than the functional index in this patient population. Last, we did not find an ideal control sample i.e., age and gendered matched controls with the same education level, CAPS scores, and disease history as the study subjects, but who were not suffering from AVHs. This limits the information that can be gained from the present study.
Conclusion
This is the first study to report that add-on aripiprazole treatment improved AVHs and other symptoms in patients with PTSD. Post outcomes analysis revealed that AVHs were alleviated by aripiprazole (AHRS score reduced ≥ 50%) in 22.7% of patients with PTSD. Functional connectivity in the SN was decreased to a greater extent in patients in whom AHRS scores were reduced ≥ 50% following add-on aripiprazole treatment compared to patients in whom AHRS scores were reduced < 50%. The decrease in functional connectivity within the SN was significantly correlated with the reduction in total AHRS score. Despite its design limitations, the findings from this study provide new insights into the pathological features and effects of treatment in patients with PTSD experiencing AVHs.
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